Relmada Therapeutics Inc (RLMD NASDAQ) stock market data APIs
$4.9418
0.5(10.1%)
as of August 7, 2026
Try our APIs with
free plan!
Relmada Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Prev. Close
4.9418
Open
5.4425
High
5.5765
Low
4.8378
52 wk Range
0.5558-8
Market Cap
527 M
Shares Outstanding
107 M
EPS
-0.11
Beta
0.833
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Relmada Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Relmada Therapeutics Inc data using free add-ons & libraries
Get Relmada Therapeutics Inc Fundamental Data
Relmada Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -13 855 048
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Relmada Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Relmada Therapeutics Inc News
New
Relmada Therapeutics Q2 Earnings Call Highlights
Key Points Interested in Relmada Therapeutics, Inc.? Here are five stocks we like better. NDV-01 manufacturing is Relmada's immediate priority as it targets an investigational new drug application (I...
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLE...
Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data f...
After-Hours Earnings Report for May 12, 2026 : FNV, NXT, OKLO, KRMN, REZI, ATRO, CAPR, AIP, EVLV, KURA, RLMD, GAIN
The following companies are expected to report earnings after hours on 05/12/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Franco-Nevada Corporation (FNV)is repo...
Get Relmada Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
